ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Section 7606: Hemp in University Labs, CBD Advantages in Pediatric Care (Part 1)"
Episode Synopsis
Part I investigates the federal hinge that enabled today's CBD scenario via a minor provision: Section 7606 of the 2014 Farm Bill.
This section enabled universities and state agricultural agencies to grow hemp for research purposes, unwittingly establishing the first legal road for contemporary cannabinoid study in more than 70 years.
It created the structural circumstances that would ultimately sustain a multibillion-dollar market.
This episode discusses the distinction between legality and legibility.
CBD's early legitimacy was established by clinical data arising from pediatric neurology, including efficacy evidence for Dravet and Lennox-Gastaut syndrome. These reports provided a very strong therapeutic signal for cannabinoids in 21st century U.S. medicine, resulting in Epidiolex, the FDA's first cannabis-derived treatment. However, as we'll see in part 2, the scientific data is not broadly understood by the wellness industry.
Part I establishes the foundation: a federal research provision, a scientific signal strong enough to resist regulatory examination, and the ambiguity that would characterize what followed it from 2018 to 2025.
This section enabled universities and state agricultural agencies to grow hemp for research purposes, unwittingly establishing the first legal road for contemporary cannabinoid study in more than 70 years.
It created the structural circumstances that would ultimately sustain a multibillion-dollar market.
This episode discusses the distinction between legality and legibility.
CBD's early legitimacy was established by clinical data arising from pediatric neurology, including efficacy evidence for Dravet and Lennox-Gastaut syndrome. These reports provided a very strong therapeutic signal for cannabinoids in 21st century U.S. medicine, resulting in Epidiolex, the FDA's first cannabis-derived treatment. However, as we'll see in part 2, the scientific data is not broadly understood by the wellness industry.
Part I establishes the foundation: a federal research provision, a scientific signal strong enough to resist regulatory examination, and the ambiguity that would characterize what followed it from 2018 to 2025.
In God we trust